<DOC>
	<DOCNO>NCT01126580</DOCNO>
	<brief_summary>The purpose study determine LY2189265 safe effective reducing glycosylated hemoglobin ( HbA1c ) compare metformin participant Type 2 Diabetes .</brief_summary>
	<brief_title>A Study Participants With Type 2 Diabetes Mellitus ( AWARD-3 )</brief_title>
	<detailed_description>The term rescue therapy trial define primarily additional nontrial antidiabetic medication management severe , persistent hyperglycemia alternative antidiabetic medication follow study drug discontinuation . For efficacy analysis , participant receive rescue medication include analysis population , measurement obtain prior take rescue therapy include efficacy analysis . For safety analysis , exception hypoglycemia outcome , measurement include obtain take rescue therapy include analysis .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Dulaglutide</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Have type 2 diabetes great equal 3 month less equal 5 year base disease diagnostic criterion ( refer World Health Organization 's [ WHO ] Classification Diabetes ) . Are treatmentna√Øve , optimally control diet exercise alone , take 1 oral antihyperglycemic medication ( OAM ) monotherapy ( exclude thiazolidinediones ) . For 1 OAM , dose must less equal 50 % maximum authorize per local label . Are able willing tolerate minimum dose 1500 milligram per day ( mg/day ) 2000 mg/day metformin . Have glycosylated hemoglobin ( HbA1c ) great equal 6.5 % less equal 9.5 % . Females childbearing potential ( surgically sterilize menarche 1year postmenopausal ) must : ) test negative pregnancy screen base serum pregnancy test , b ) agree use reliable method birth control study 1 month follow last dose study drug ; c ) breastfeeding . Have stable weight ( plus minus 5 % ) great equal 3 month prior screen . Have body mass index ( BMI ) 23 45 kilogram per square meter ( kg/m^2 ) , inclusive . Are wellmotivated , capable , willing : ) perform selfmonitored blood glucose ( SMBG ) testing ; b ) learn selfinject treatment ( LY2189265 placebo ) c ) maintain study diary . Have type 1 diabetes mellitus . Are treat follow medication : ) chronically treated insulin treatment diabetes past ; however , shortterm use insulin 3 month prior screen allowable , b ) glucagonlike peptide 1 ( GLP1 ) analog within 3 month prior screen , c ) drug cause weight loss within 3 month prior screen , ) thiazolidinediones ( TZDs ) within 3 month prior screen , e ) chronically treat ( great equal 14 day ) oral glucocorticoid receive type therapy within 4 week prior screen , f ) illegal drug . Have 1 case uncontrolled diabetes require hospitalization 6 month prior screen . Have stomach problem , chronically take medication increase movement digestive tract slow empty digestive tract , gastric bypass ( bariatric ) surgery . Have problem heart brain past 2 month prior screen , heart attack , chest pain , heart failure , heart bypass operation , angioplasty stent insertion , heart rhythm problem , stroke . Have serum creatinine result show great equal 1.5 milligram per deciliter ( mg/dL ) men great equal 1.4 mg/dL woman . Have problem liver pancreas . Have creatinine clearance result show less 60 milliliter per minute ( mL/min ) , evidence significant active , uncontrolled endocrine ( hormone ) , active autoimmune abnormality . Have serum calcitonin test show great equal 20 picograms per milliliter ( pcg/mL ) time screen . Have family history medullary Ccell hyperplasia endocrine neoplasia type 2A type 2B . Have cancer ( except skin cancer ) remission cancer le 5 year . Have organ transplant except corneal transplant . Have receive treatment within last 30 day drug regulatory approve . Have participate medical , surgical , pharmaceutical study type procedure perform within 30 day prior screen . Have condition contraindication would interfere medication provide study treat diabetes . Have blood disorder would interfere draw blood glucose measurement lab sample . Have previously participate sign informed consent document type study study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>